Group 1: Shareholding Changes - Company Zhaoyi Innovation announced that several directors and senior management personnel plan to reduce their holdings by a total of 249,000 shares, with specific reductions from the vice chairman and general manager, as well as other vice presidents [1] - Company Super Aerospace announced a stock suspension due to its controlling shareholders planning a significant matter that may lead to a change in control [2] - Company Haosai is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [5] Group 2: Major Contracts and Projects - Company Dajin Heavy Industry's wholly-owned subsidiary signed a contract worth approximately 1.339 billion yuan for a European offshore wind farm project, which represents 35.41% of the company's audited revenue for 2024 [3] - Company Ruifeng New Materials plans to increase capital by 200 million yuan in a related party to advance a lithium hexafluorophosphate project [6] Group 3: Regulatory Actions - Company Jushi Chemical received a notice from the CSRC regarding an investigation for suspected violations of information disclosure laws [4] - Company Huosai is also under investigation by the CSRC for similar reasons [5] Group 4: Investment and Acquisitions - Company Gao Neng Environment plans to acquire 45.2% equity in three mining companies [7] - Company Aerospace Electric intends to purchase 32% equity in Shenzhen Aerospace Electric Motor System Co., Ltd. through public bidding [8]

Core Viewpoint - The company has received registration approval from the National Medical Products Administration for its single-use pressure monitoring cardiac pulsed electric field ablation catheter, enhancing its product portfolio in arrhythmia treatment [1] Group 1: Product Development - The newly approved product utilizes a strain gauge-based pressure sensor design combined with pulsed electric field technology, magnetic field positioning technology, and saline infusion technology [1] - This catheter is designed to work in conjunction with cardiac pulsed electric field ablation devices for arrhythmia treatment [1] Group 2: Market Positioning - The product can provide real-time measurement of contact pressure between the catheter tip and the heart wall, as well as positional information within the heart when used with a three-dimensional cardiac electrophysiology mapping system [1] - The registration of this medical device allows the company to synergize its three major ablation energy products: radiofrequency, cryoablation, and pulsed electric field, thereby offering more treatment options for arrhythmia [1] - This development is expected to enhance the company's core competitiveness and market expansion capabilities [1]

证券代码：688351 证券简称：微电生理 公告编号：2025-028 上海微创电生理医疗科技股份有限公司 关于一次性使用压力监测心脏脉冲电场消 融导管获批上市的自愿披露公告 上海微创电生理医疗科技股份有限公司董事会 2025 年 11 月 22 日 1 近日，上海微创电生理医疗科技股份有限公司（以下简称"公司"）一次性 使用压力监测心脏脉冲电场消融导管获得国家药品监督管理局注册申请（国械注 准 20253012351）。该产品基于应变片原理的压力传感器设计，结合脉冲电场技 术、磁场定位技术、盐水灌注技术，与心脏脉冲电场消融设备配合使用，可用于 心律失常治疗；与三维心脏电生理标测系统配合使用，可提供导管在心内的位置 信息以及进行导管头端和心壁之间触点压力的实时测量。上述医疗器械注册证的 取得，实现了公司"射频+冷冻+脉冲"三大消融能量产品的协同布局，为心律失 常治疗提供了更多选择，有利于进一步增强公司的核心竞争力和市场拓展能力。 上述注册申请的取得仅代表一次性使用压力监测心脏脉冲电场消融导管获 得国内市场准入资格，产品上市后的实际销售情况受到多重因素影响，目前尚无 法预测其对公司未来业务的具体影响。敬请广大投 ...

华宝中证医疗ETF（512170）基金经理为胡洁。 截至发稿，胡洁累计任职时间13年39天，现任基金资产总规模1002.04亿元，任职期间最佳基金回报 183.07%， 任职期间最差基金回报-98.01%。 11月20日，微电生理涨5.45%，截至发稿，报23.98元/股，成交6316.65万元，换手率2.19%，总市值 112.85亿元。 责任编辑：小浪快报 资料显示，上海微创电生理医疗科技股份有限公司位于上海市浦东新区周浦镇天雄路588弄1-28号第28 幢，成立日期2010年8月31日，上市日期2022年8月31日，公司主营业务涉及电生理介入诊疗与消融治疗 领域创新医疗器械研发、生产和销售。主营业务收入构成为：导管类产品71.77%，其他产品20.22%， 设备类产品7.24%，租赁服务0.77%。 从微电生理十大流通股东角度 数据显示，华宝基金旗下1只基金位居微电生理十大流通股东。华宝中证医疗ETF（512170）三季度减 持57.49万股，持有股数403.74万股，占流通股的比例为3.23%。根据测算，今日浮盈赚取约500.64万 元。 华宝中证医疗ETF（512170）成立日期2019年5月20日 ...

Core Viewpoint - The stock of Shanghai Microelectronic Physiological Technology Co., Ltd. has experienced fluctuations, with a current price of 23.31 CNY per share, reflecting a year-to-date increase of 22.43% but a recent decline of 4.47% over the last five trading days [1] Group 1: Company Overview - Shanghai Microelectronic Physiological Technology Co., Ltd. was established on August 31, 2010, and went public on August 31, 2022. The company specializes in the research, development, production, and sales of innovative medical devices in the field of electrophysiological intervention and ablation therapy [1] - The company's revenue composition includes catheter products (71.77%), other products (20.22%), equipment (7.24%), and leasing services (0.77%) [1] Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 336 million CNY, representing a year-on-year growth of 15.65%. The net profit attributable to shareholders was 41.92 million CNY, with a slight increase of 0.46% year-on-year [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 9,580, up by 9%. The average number of circulating shares per person decreased by 8.26% to 13,033 shares [2] - The top circulating shareholder is Huatai-PineBridge Innovation Medicine Mixed A, holding 4.7284 million shares, an increase of 308,600 shares from the previous period. Other notable shareholders include Huatai-PineBridge Medical Service Flexible Allocation Mixed A and Hua Bao Zhong Zheng Medical ETF, with varying changes in their holdings [3]

证券代码：688351 证券简称：微电生理 公告编号：2025-027 上海微创电生理医疗科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 本次会议召开及表决方式符合《中华人民共和国公司法》（以下简称《公司 法》）及《上海微创电生理医疗科技股份有限公司章程》（以下简称《公司章程》） 的有关规定。本次会议由公司董事会召集，公司董事长顾哲毅先生主持。 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 12 日 （二） 股东大会召开的地点：上海市浦东新区周浦镇天雄路 588 弄 23 号楼 3 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 61 | | --- | --- | | 普通股股东人数 | 61 | | 2、出席会议的股东所持有的表决权数量 | 358,487,873 | | 普通股股东所持有表 ...

北京世辉律师事务所 关于上海微创电生理医疗科技股份有限公司 2025 年第一次临时股东大会的 致：上海微创电生理医疗科技股份有限公司 北京世辉律师事务所（以下简称"本所"）为具有从事法律业务资格的律师事 务所。本所接受上海微创电生理医疗科技股份有限公司（以下简称"公司"）的委 托，指派本所律师根据《中华人民共和国公司法》《中华人民共和国证券法》（以 下简称"《证券法》"）《上市公司股东会规则》等有关法律、法规、规范性文件 （以下统称"法律法规"）及《上海微创电生理医疗科技股份有限公司章程》（以 下简称"《公司章程》"）的规定，就公司 2025 年第一次临时股东大会（以下简 称"本次股东大会"）相关事宜出具本法律意见书。 本所及本所律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日 以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信 用原则，进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完 整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗 漏，并承担相应法律责任。 为出具本法律意 ...

Core Viewpoint - The stock of Microelectrophysiology has experienced fluctuations, with a recent decline of 2.05% and a year-to-date increase of 25.53% [1][2]. Company Overview - Shanghai Microelectrophysiology Medical Technology Co., Ltd. was established on August 31, 2010, and went public on August 31, 2022. The company specializes in innovative medical devices for electrophysiological intervention and ablation treatment [2]. - The revenue composition of the company includes catheter products (71.77%), other products (20.22%), equipment (7.24%), and leasing services (0.77%) [2]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 336 million yuan, representing a year-on-year growth of 15.65%. The net profit attributable to the parent company was 41.92 million yuan, with a slight increase of 0.46% year-on-year [2]. Stockholder Information - As of September 30, 2025, the number of shareholders increased to 9,580, while the average circulating shares per person decreased by 8.26% to 13,033 shares [2]. - The top circulating shareholders include: - Huatai-PineBridge Innovation Medicine Mixed A (006113) as the largest shareholder with 4.7284 million shares, an increase of 308,600 shares from the previous period [3]. - Huatai-PineBridge Medical Service Flexible Allocation Mixed A (001417) as the second-largest shareholder with 4.2609 million shares, a decrease of 298,360 shares [3]. - Hong Kong Central Clearing Limited entered as a new shareholder with 1.8701 million shares [3].

Macroeconomic Insights - Global asset performance shows mixed results, with the Hang Seng Index up 1.29% and the Shanghai Composite Index up 1.08%, while developed markets like the S&P 500 fell by 1.63%[6] - In October, the U.S. ISM Manufacturing PMI declined, indicating economic slowdown, while consumer confidence continued to drop according to the University of Michigan index[7] Inflation and Prices - October CPI in China rose by 0.2% year-on-year, while PPI decreased by 2.1%, indicating a stable inflation environment with core service prices reaching their highest level since March 2024[11] - The rise in core CPI is attributed to reduced food drag and increased service contributions, with gold prices significantly impacting jewelry costs[13] Trade and Exports - In October, China's exports fell by 1.1% year-on-year, while imports grew by 1.0%, leading to a slight decrease in trade surplus[16] - The export structure shows weakness in non-U.S. markets, particularly the EU, while exports to the U.S. and ASEAN remained strong[18] Investment Strategies - The asset allocation report suggests an overweight position in Chinese A-shares and industrial commodities, with equity allocation set at 45% and bonds at 45%[22] - The report emphasizes the importance of AI industry trends and the potential for volatility in global equity markets, recommending a focus on quality assets[23] Market Dynamics - The trading activity has decreased, with turnover rates and transaction volumes declining across indices, indicating a cautious market sentiment[28] - The report highlights a decrease in northbound capital flow, with a net outflow of 2.6 billion CNY in the recent week, reflecting investor sentiment shifts[34]

Core Insights - The company reported a revenue of 336 million yuan for the first three quarters of 2025, representing a year-on-year growth of 15.65% [1] - The net profit attributable to the parent company was 42 million yuan, with a slight increase of 0.46% year-on-year, while the net profit excluding non-recurring gains and losses surged by 3297.94% to 24 million yuan [1] - In Q3 2025 alone, the company achieved a revenue of 113 million yuan, marking a year-on-year increase of 21.78%, but the net profit attributable to the parent company decreased by 62.56% to 9 million yuan [1] Business Performance - The company ranks first among domestic manufacturers in three-dimensional electrophysiology surgery, with over 1,000 hospitals covered and more than 80,000 surgeries completed [2] - The FireMagic? Trueforce? disposable pressure monitoring magnetic positioning radiofrequency ablation catheter has seen increasing clinical acceptance, with over 3,000 radiofrequency ablation surgeries completed in multiple medical centers [2] - International market revenue grew by over 40% year-on-year in H1 2025, with successful market entries in Mexico, the UK, and Rwanda [2] Product Development - The company has a rich pipeline of products, with its self-developed pressure pulse PFA product submitted for registration and expected to be approved within the year [3] - The second-generation nanosecond pulse product from the affiliated company Shangyang Medical has completed clinical enrollment and is in the follow-up stage [3] - The company’s ICE and RDN products have been included in the national green channel for innovative products, indicating strong future growth potential [3] Financial Projections - Revenue projections for 2025-2027 are 463 million yuan, 631 million yuan, and 829 million yuan, with year-on-year growth rates of 12.18%, 36.24%, and 31.36% respectively [3] - Net profit attributable to the parent company is expected to be 72 million yuan, 108 million yuan, and 157 million yuan for the same period, with growth rates of 37.79%, 50.92%, and 45.10% respectively [3] - Corresponding PE ratios for 2025-2027 are projected at 165x, 109x, and 75x, with PEG ratios of 4.37, 2.15, and 1.67 [3]